Overview

The Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Mild and Moderate COVID-19

Status:
Recruiting

Trial end date:
2021-10-31

Target enrollment:

Participant gender:

Summary

The purpose of this clinical trial is to assess the safety and efficacy of Clevudine 150 mg versus placebo once daily administration with standard of care therapy for 10 days in patients with mild and moderate COVID-19.

Phase:

Phase 2

Details

Lead Sponsor:

Bukwang Pharmaceutical

Treatments:

Clevudine